Five-Year ADlong Data on Lebrikizumab for Atopic Dermatitis Presented

Lebrikizumab has now accumulated five years of follow-up in the ADlong extension study, a milestone Stephan Weidinger, MD, PhD, laid out for clinicians tracking long-term atopic dermatitis therapy.

The interview, published by HCPLive, centers on the open-label extension data covering half a decade of treatment with the IL-13–targeting biologic in patients with moderate-to-severe atopic dermatitis. Weidinger, who heads the dermatology department at the University Hospital Schleswig-Holstein in Kiel, Germany, walks through what sustained exposure means for patients who started in the parent pivotal trials.

Why do five-year eczema data matter?

Atopic dermatitis is a chronic, relapsing disease. Regulatory approval packages rest on 16-week pivotal endpoints — typically EASI 75 or EASI 90 response and validated itch scores — but those windows say little about how a biologic performs over years of real use.

Extension studies like ADlong exist to close that gap. They follow randomized-trial participants into open-label treatment, capturing durability of response, safety signals that only emerge with time, and the practical question of whether patients keep taking the drug.

For clinicians, that's the evidence base that informs decisions about staying the course versus switching mechanisms. It's also the evidence base payers consult when they weigh coverage of a chronic-therapy biologic against cheaper alternatives.

What is lebrikizumab?

Lebrikizumab is a monoclonal antibody designed to bind interleukin-13 with high affinity and block signaling through the IL-13 receptor alpha-1 and alpha-2 subunits. IL-13 sits at the center of the type 2 inflammatory cascade that drives atopic dermatitis, making it a rational target for the disease.

The agent won approval for moderate-to-severe atopic dermatitis on the strength of its pivotal program, and the ADlong extension carries that population forward into long-term follow-up. The five-year mark now reported places lebrikizumab among the biologics with the longest continuous datasets in this indication.

How does Weidinger frame the results?

Weidinger's discussion, per HCPLive, focuses on what the extended observation adds for practice rather than restating single-endpoint figures. His vantage point is notable: he has been a leading investigator across the lebrikizumab program and a prominent voice in European atopic dermatitis trial design.

The conversation forms part of HCPLive's conference and interview coverage, where trial investigators interpret extension data for a clinical audience. Readers should consult the primary ADlong publications for the full efficacy tables and safety summaries, as the interview format condenses them.

What should dermatologists watch next?

Long-term extension data tend to answer durability questions and raise new ones: how response holds up in patients who step down dosing frequency, which adverse events accumulate over years, and how the profile compares with other IL-13 and IL-4/IL-13 agents in the class.

Weidinger's commentary signals that the five-year dataset is now part of that comparative conversation. As more atopic dermatitis biologics reach similar follow-up horizons, clinicians will increasingly choose among agents on long-term evidence rather than week-16 snapshots.

The ADlong five-year results, and Weidinger's read of them, suggest lebrikizumab's evidence base is maturing along with the field.